Sai Life Sciences closes trading window from Oct 1 for Q2FY27 results

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Trading window closed from October 1, 2026, for Q2FY27 results
  • Restriction applies to designated persons and immediate relatives
  • Window reopens 48 hours after financial results announcement
  • Board meeting date to be announced later
powered bylight_fuzz_icon
52120717

*this image is generated using AI for illustrative purposes only.

Sai Life Sciences Limited has closed its trading window effective October 1, 2026, in preparation for the declaration of unaudited financial results for the second quarter and half year ending September 30, 2026.

The closure applies to all designated persons and their immediate relatives as per the company's code of conduct. This measure ensures compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, preventing any dealing in the company's securities during the sensitive period.

Trading restrictions and timeline

The trading window remains closed until the end of 48 hours after the announcement of the Q2FY27 results. During this period, insiders are prohibited from entering any transaction involving the buying or selling of Sai Life Sciences shares.

Event Date / Timeline
Trading window closure start October 1, 2026
Financial period covered Q2FY27 and H1FY27 (ending Sep 30, 2026)
Trading window reopening 48 hours after results announcement
Board meeting date To be intimated in due course

Regulatory compliance

The company filed this notice with both the National Stock Exchange of India Limited and BSE Limited on September 28, 2026. The filing was signed by Runa Karan, Company Secretary and Compliance Officer. The specific date for the board meeting to consider and approve the financial results has not yet been disclosed and will be communicated separately.

Historical Stock Returns for Sai Life Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.38%-0.90%+8.97%+56.68%+79.92%+107.43%

How will Sai Life Sciences' Q2FY27 revenue growth compare to the previous quarter given the current global CDMO demand environment?

What impact might the upcoming financial results have on the company's stock volatility once the trading window reopens?

Are there any anticipated changes in capital expenditure guidance for FY27 that could influence investor sentiment post-results?

Sai Life Sciences shareholders approve FY26 results, re-appoint CEO

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Sai Life Sciences shareholders adopted FY26 audited financial statements at the 27th AGM held on September 17, 2026.
  • The re-appointment of Managing Director Krishnam Raju Kanumuri passed with 99.02% support, despite 1.82% dissent from public institutions.
  • Promoter shareholders voted 100% in favour on both resolutions, holding 73.29 million shares.
  • Total votes polled exceeded 189 million, with remote e-voting conducted via KFin Technologies.
powered bylight_fuzz_icon
51179922

*this image is generated using AI for illustrative purposes only.

Sai Life Sciences shareholders adopted the audited standalone and consolidated financial statements for FY26 at the company’s 27th Annual General Meeting (AGM). The meeting was held on September 17, 2026, via video conferencing.

The event transacted ordinary business items as outlined in the notice. Shareholders also approved the re-appointment of Mr. Krishnam Raju Kanumuri as a director, replacing himself upon retirement by rotation.

Meeting Proceedings

The AGM commenced at 10:30 am with Dr. Kanumuri Ranga Raju, Chairman and Whole Time Director, calling the meeting to order. Due to technical issues, Mr. Sivaramakrishnan Chittor, Whole-Time Director and Chief Financial Officer, addressed the shareholders on behalf of Mr. Krishnam Raju Kanumuri, Managing Director and Chief Executive Officer.

Mr. Chittor presented an overview of the company’s financial performance for FY26. He highlighted key operational achievements and outlined the growth strategy expected to drive value creation for stakeholders.

Key Attendees

The following directors were present at the meeting:

  • Dr. Kanumuri Ranga Raju, Chairman & Whole Time Director
  • Mr. Krishnam Raju Kanumuri, Managing Director & CEO
  • Mr. Sivaramakrishnan Chittor, Whole-time Director & CFO
  • Mr. Dinesh Vinoobhai Patel, Independent Director
  • Mr. Ramesh Ganesh Iyer, Independent Director
  • Ms. Suchita Sharma, Independent Director

Ms. Runa Karan, Company Secretary & Compliance Officer, welcomed members and confirmed compliance with Ministry of Corporate Affairs and SEBI circulars regarding virtual meetings.

Voting Results and Analysis

Remote e-voting facilities were provided through KFin Technologies Limited from September 14 to September 16, 2026. Mr. DSM Ram was appointed as the scrutinizer for the voting process. The record date for the meeting was September 10, 2026.

Members holding 7,76,98,047 equity shares participated in the meeting. The auditor’s report contained no qualifications, observations, or adverse comments on the financial statements. Similarly, the secretarial audit report had no adverse remarks.

The meeting concluded at 11:25 am after all resolutions were passed with the requisite majority. Below are the detailed voting outcomes for the two ordinary resolutions considered.

Resolution 1: Adoption of Financial Statements

The resolution to adopt the Audited Standalone and Consolidated Financial Statements for the year ended March 31, 2026, received overwhelming support. Promoter group shareholders voted 100% in favour. Among public shareholders, institutional investors also voted unanimously in favour, while non-institutional public shareholders recorded negligible dissent.

Category Votes Polled Votes In Favour % In Favour Votes Against % Against
Promoter Group 73,294,675 73,294,675 100.00% 0 0.00%
Public - Institutions 102,037,408 102,037,408 100.00% 0 0.00%
Public - Non Institutions 14,223,273 14,223,154 99.99% 119 0.00%
Total 189,555,356 189,555,237 99.99% 119 0.00%

Resolution 2: Re-appointment of Director

The resolution to re-appoint Mr. Krishnam Raju Kanumuri as a director passed with a majority, though it faced notable dissent from public institutional investors. While promoter shareholders voted unanimously in favour, public institutions cast approximately 1.82% of their polled votes against the resolution. Non-institutional public shareholders largely supported the re-appointment.

Category Votes Polled Votes In Favour % In Favour Votes Against % Against
Promoter Group 73,294,675 73,294,675 100.00% 0 0.00%
Public - Institutions 102,050,969 100,191,295 98.18% 1,859,674 1.82%
Public - Non Institutions 14,223,273 14,223,100 99.99% 173 0.00%
Total 189,568,917 187,709,070 99.02% 1,859,847 0.98%

Scrutinizer Report Details

The consolidated scrutinizer report, issued by DSM Ram of DSMR & Associates, confirmed that the e-voting process complied with Section 108 of the Companies Act, 2013 and relevant SEBI Listing Regulations. The report noted that invalid votes were primarily from public institutions, totaling 110,460 votes for Resolution 1 and 96,899 votes for Resolution 2.

Historical Stock Returns for Sai Life Sciences

1 Day5 Days1 Month6 Months1 Year5 Years
-0.38%-0.90%+8.97%+56.68%+79.92%+107.43%

What specific growth strategies did Mr. Chittor outline to drive value creation for stakeholders in the upcoming fiscal year?

How might the 1.82% dissent from public institutional investors regarding Mr. Kanumuri's re-appointment impact future corporate governance dynamics or investor relations?

Given the unanimous approval of financials, what are the projected revenue and profit margins for FY27 based on the operational achievements highlighted?

More News on Sai Life Sciences

1 Year Returns:+79.92%